6.175USD-0.24%Mkt Cap: 375.85M USDP/E: —Last update: 2026-05-26
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's commercial portfolio includes Fanapt for…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
105.81BDKKP/E 20.4
66.47BUSDP/E 15.5
46.56BEURP/E 30.5
43.89BEURP/E 36.5
39.41BUSDP/E 74.0
32.84BUSD—
32.05BSEKP/E 47.4
Indicators:|
Key Statistics
Company
Market Cap375.85M USD
Enterprise Value184.20M USD
Revenue (TTM)217.78M USD
Gross Profit203.06M USD
Net Income (TTM)-220.47M USD
Revenue/Share3.681 USD
Last Price6.175 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees533
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)31.05
PEG2.23
EV/EBITDA-1.21
EV/Revenue0.85
P/S1.71
P/B1.12
EPS (TTM)-4.06
EPS (Forward)0.20
52W Range
4.14035% of range9.940
52W High9.940 USD
52W Low4.140 USD
Profitability
Gross Margin93.96%
Oper. Margin-97.11%
EBITDA Margin-69.78%
Profit Margin-102.02%
ROE-67.38%
ROA-45.09%
Growth
Revenue Growth3.40%
Earnings Growth—
Cash Flow & Leverage
Operating CF-109.44M USD
CapEx (TTM)998.00K USD
FCF Margin-38.18%
FCF Yield-22.12%
Net Debt-189.24M USD
Net Debt/EBITDA1.25
Balance Sheet
Debt/Equity0.04
Current Ratio2.16
Quick Ratio1.91
Book Value/Sh5.536 USD
Cash/Share3.364 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.4 (Strong Buy)
Target (Mean)14.90 USD
Target Range7.500 USD – 21.00 USD
# Analysts5
Ownership
Shares Out.60.14M
Float53.82M
Insiders6.12%
Institutions78.66%
Short Interest
Short Ratio5.7d
Short % Float10.82%
Short % Out.10.30%
Shares Short6.20M
Short (prev mo.)5.31M
Technical
SMA 507.104 (-13.1%)
SMA 2006.239 (-1.0%)
Beta0.65
S&P 52W Chg28.31%
Avg Vol (30d)1.13M
Avg Vol (10d)1.11M
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—